Anergis, an Epalinges, Switzerland-based clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies, has closed a CHF18m Series A financing round.
The round was co-led by Vinci Capital-Renaissance PME, BioMedInvest and Sunstone Capital. They were joined by Esperante, Initiative Capital Romandie and private investors.
In conjunction with the funding, Patrick Scherrer representing Vinci Capital-Renaissance PME, Markus Hosang representing BioMedInvest and Sten Verland representing Sunstone Capital have joined Anergis’ Board of Directors.
The Board will be chaired by André J. Mueller, a professional with executive and non-executive experience in biotech ventures.
The funds will be used to cover the company’s financial requirements for the next two years. Anergis will conduct a large Phase II multicenter trial with AllerT, its lead product for patients allergic to birch pollen, and will accelerate the preclinical development of its product portfolio in new research laboratories.
The company is led by CEO Vincent Charlon, PhD.